Mouwasat Medical Services Company (4002) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended 30 September 2025 reached SR 2.34 billion, up from SR 2.12 billion year-over-year, with net profit rising to SR 606.6 million from SR 489.9 million.

• Gross profit for the nine-month period increased to SR 1.03 billion from SR 971.2 million year-over-year.

• Total assets grew to SR 5.91 billion as of 30 September 2025, compared to SR 5.40 billion at year-end 2024.

• The company maintained compliance with all loan covenants and continued expansion projects.

Financial highlights

• Revenue for Q3 2025 was SR 777.3 million, up from SR 710.7 million in Q3 2024.

• Net profit for Q3 2025 was SR 207.1 million, compared to SR 154.2 million in Q3 2024.

• Basic and diluted EPS for the nine months was SR 2.92, up from SR 2.37 year-over-year.

• Cash and cash equivalents at period end were SR 467.0 million, up from SR 426.6 million at year-end 2024.

• Operating cash flow for the nine months was SR 814.6 million, compared to SR 811.5 million year-over-year.

Outlook and guidance

• A proposed interim dividend of SR 1 per share (SR 200 million) for H1 2025 is pending shareholder approval.

• Ongoing expansion projects with capital commitments of SR 273.1 million as of 30 September 2025.